OBJECTIVE:To study relative bioavailability of dauricine self-microemulsifying drug delivery system (SMEDDS) in rats. METHODS:12 rats were randomly divided into dauricine SMEDDS group (20 mg/kg) and dauricine solution group (50 mg/kg),6 rats in each group. They were given relevant medicine intragastrically. Then,0.3 ml plasma was collected from orbital venous plexus before medication and 0.167,0.333,0.5,0.75,1,2,4,8,12,24,36 h after medication. The plasma concentration of da- uricine was determined by HPLC-MS/MS,and DAS 3.0 was used to calculate pharmacokinetic parameters and evaluate the relative bioavailability of dauricine with dauricine SMEDDS. RESULTS:The linear range of dauricine in plasma were 2.12-424 ng/ml (r=0.999 9);RSDs of intra-day and inter-day were all lower than 10%. Pharmacokinetic parameters of dauricine solution and dau-ricine SMEDDS were that cmax were(126.3±37.4)ng/ml and(179.6±51.5)ng/ml;t1/2 were(11.48±4.58)and(21.79±6.59)h;AUC0-t were (1 963.5±638.3)ng·h/ml and(2 535.8±739.5)ng·h/ml;AUC0-∞ were(2 256.3±703.5)ng·h/ml and(2 854.6± 768.7)ng·h/ml,respectively. The relative bioavailability of dauricine SMEDDS were 323% and 316% by calculating with AUC0-t and AUC0-∞,respectively. CONCLUSIONS:Intragastric administration of dauricine SMEDDS can improve relative bioavailability of dauricine significantly.

Objective: To investigate the correlation of single nucleotide polymorphisms (SNPs) in autophage-related 5 ( ATG5 ) gene promoter with acute myocardial infarction (AMI). Methods: The SNPs of ATG5 gene promoter were detected by polymerase chain reaction (PCR) and Sanger sequencing. The typing and correlation of SNPs in 378 AMI patients and 374 healthy controls were analyzed by Chi-square test, Logistic regression analysis and haplotype analysis. Results: Two SNPs of ATG5 gene promoter, rs506027 (OR=1.4, 95% CI \[0.6-3.0\], P=0.411) and rs510432 (OR=1.6, 95% CI \[0.7-3.4\], P=0.275), were found. They didn′t increase the susceptibility of AMI, and the haplotype associated with AMI was not found in the two SNPs. Conclusion The polymorphism of ATG5 gene promoter isn′t associated with the susceptibility of AMI.